Glass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience
Neos also has a development candidate, NT0502, for the treatment of sialorrhea in patients with neurological conditions.
- Neos also has a development candidate, NT0502, for the treatment of sialorrhea in patients with neurological conditions.
- This communication discusses the proposed merger transaction pursuant to the terms of the Agreement and Plan of Merger, dated as of December 10, 2020, by and among Neos Therapeutics, Inc. (Neos), Aytu BioScience, Inc. (Aytu), and Neutron Acquisition Sub, Inc. (the Merger Agreement).
- The registration statement was declared effective on February 9, 2021 and the joint proxy statement/prospectus was first mailed to stockholders of Neos and Aytu on or about February 12, 2021.
- Aytu and Neos also plan to file other relevant documents with the SEC regarding the proposed merger transaction.